BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia

Oncogene

Volumn 32, Issue 13, 2013, Pages 1670-1681

  Kuroda, I ^a   Inukai, T ^a   Zhang, X ^a,f   Kikuchi, J ^b   Furukawa, Y ^a   Nemoto, A ^a   Akahane, K ^a   Hirose, K ^a   Honna Oshiro, H ^a   Goi, K ^a   Kagami, K ^a   Yagita, H ^c   Tauchi, T ^d   Maeda, Y ^e   Sugita, K ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

BCR ABL; Philadelphia chromosome positive leukemia; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

BCR ABL PROTEIN; DASATINIB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; IMATINIB; LENTIVIRUS VECTOR; NILOTINIB; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG SPECIFICITY; GENE INACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DOWN REGULATION;

CELL LINE, TUMOR; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHILADELPHIA CHROMOSOME; PROTEIN KINASE INHIBITORS; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84875876348     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.186     Document Type: Article

References (41)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172.
2. Hehlmann R, Hochhaus A, Baccarani M. European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350.
3. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113: 1619-1630.
4. Preti HA, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM. Philadelphiachromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients. Am J Med 1994; 97: 60-65.
5. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group. Cancer 1998; 83: 2030-2039.
6. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
8. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blastic crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
9. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2010; 24: 6-12.
10. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W et al. Predictive factors for outcome and response in patients treated with secondgeneration tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 2011; 117: 1822-1827.
11. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
12. Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2010; 116: 3409-3417.
13. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2003; 103: 767-776.
14. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-4383.
15. Kagi D, Vignaux F, Ledermann B, Depraetere V, Nagata S, Hengartner H et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
16. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-652.
17. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001; 193: 661-670.
18. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7: 94-100.
19. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356-1361.
20. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195: 161-169.
21. Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 2002; 8: 1433-1437.
22. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007; 26: 3745-3757.
23. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113.
24. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and death domain-containing receptor for TRAIL. Science 1997; 277: 815-821.
25. Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A et al. TNF-related apoptosisinducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 2003; 101: 3658-3667.
26. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010; 29: 4752-4765.
27. Zhang X, Inukai T, Akahane K, Hirose K, Kuroda I, Honna H et al. Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosomepositive leukemia cells to TRAIL-mediated apoptosis. Leuk Res 2011; 35: 940-949.
28. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
29. Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. Leuk Res 2009; 33: 450-459.
30. Akahane K, Inukai T, Zhang X, Hirose K, Kuroda I, Goi K et al. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis. Exp Hematol 2010; 38: 885-895.
31. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C et al. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 2001; 7: 350-357.
32. Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: Results of a prospective phase II open-label multicenter study. J Clin Oncol 2005; 23: 7583-7593.
33. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791-2793.
34. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614-4617.
35. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1009-1015.
36. Yoshimitsu M, Fujiwara H, Ozaki A, Hamada H, Matsushita K, Arima N et al. Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. Int J Hematol 2008; 88: 331-335.
37. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia- positive acute lymphoblastic leukemia (Ph ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 2009; 33: 174-177.
38. Inukai T, Sugita K, Suzuki T, Ijima K, Goi K, Tezuka T et al. A novel 203 kD aberrant BCR-ABL product in a girl with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1993; 85: 823-825.
39. Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 2001; 507: 381-385.
40. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406.
41. Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H et al. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). Blood 2010; 116: 962-970.